1. Canada Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Entheon Biomedical Corp.

Entheon Biomedical Corp.

0.03
EUR
+0.00
(-10.53%)
0.00EPS
2017 Y
2018 Y
2019 Y
2020 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
0.03
0.04
- -
- -
- -
Basic EPS, GAAP
- -
-0.36
-0.38
-0.24
-1.6
-1.64
-1.44
-0.05
-0.04
-0.02
- -
Free Cash Flow per Basic Share
-0.01
-0.57
-1.51
-0.31
-1.04
-1.05
-0.33
-0.06
-0.05
-0.02
-0.01
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.11
0.93
2.99
2.81
0.93
1.53
0.1
0.05
0.02
0.02
0.03
Tangible Book Value per Share
0.11
0.93
2.99
2.81
0.93
0.53
0.1
0.05
0.02
0.02
0.03
Basic Weighted Avg Shares
- -
- -
- -
1
3
5
6
6
8
13
16
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
-1,898.18
-124.96
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
- -
- -
- -
-4
-9
-9
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
-4,492.23
-119.85
- -
- -
- -
Working Capital
- -
- -
1
1
4
2
1
- -
- -
- -
- -
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
- -
- -
2
2
4
9
1
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
2.59
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
4.9
Return on Common Equity (%)
- -
-69.57
-14.47
-8.39
-161.13
-138.91
-176.33
-64.49
-137.9
-138.07
4.9

Capital Structure

CAD

•

in mil. unless spec.
Nov'25
Feb'26
May'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
14
14
14
Market Capitalization
1
1
- -

Working Capital

CAD

•

in mil. unless spec.
Nov'25
Feb'26
May'26
Total Current Assets
- -
- -
1
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
- -
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

CAD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
13.77%
122.97%
Free Cash Flow
- -
-11.88%
-11.52%
Net Income, GAAP
- -
2.02%
1.92%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

CAD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

CAD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.01
-0.01
-0.01
-0.01
-0.04
2025
-0.01
- -
- -
- -
-0.02
2026
- -
0.02
- -
- -
- -

Quarterly Dividends Per Share

CAD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Timothy Ko
Full Time Employees
1
Sector
Health technology
Industry
Pharmaceuticals: major
Address
999 West Broadway Vancouver BC Canada V5Z 1K5
IPO Date
May 3, 2018
Website
entheonbiomedical.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Entheon Biomedical Corp. Entheon Biomedical Corp. (CSE: ENBI) is a Vancouver, British Columbia-based biotechnology research and development company founded in 2010 that develops and commercializes therapies and genetic testing solutions for treating addiction and substance use disorders, with operations focused on North America and potential expansion into Europe. The company offers genetic-based pre-screening platforms through its wholly-owned subsidiary HaluGen Life Sciences Inc., including the Psychedelics Genetic Test Kit that evaluates individual sensitivity, risk profiles, metabolism, and adverse reactions to hallucinogenic substances such as LSD, MDMA, ayahuasca, and others via biomarkers like CYP2D6; and Lobo Genetics Inc.'s Cannabis Genetic Test Kit, which provides personalized insights into THC and CBD metabolism, psychotomimetic effects, psychosis risk, and neurocognitive impairment. Previously focused on N,N-dimethyltryptamine (DMT)-based psychedelic therapeutics, Entheon sold its Phase 1 DMT study to Cybin Inc. in 2022 and has since pivoted toward genetic testing and diagnostics. In January 2025, the company entered a binding letter of intent to acquire Mentis AI, a developer of AI companions (AmicaChat) and coaching tools (GentleGossip) for mental health and loneliness, to integrate with its genetic platforms for enhanced customer data, outcomes tracking, and personalized wellness services; the share exchange transaction, expected by February 2025, will issue approximately 11 million shares and give Mentis AI shareholders about 44.25% ownership, subject to due diligence and regulatory approvals including from the Canadian Securities Exchange. Entheon recently closed a $500,000 non-brokered private placement in early 2025 to support ongoing operations and strategic initiatives.